Trial Profile
An Open-Label, Multicenter, Dose Escalation And Expansion Study Of NKTR-214 In Subjects With Locally Advanced Or Metastatic Solid Tumor Malignancies
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Bempegaldesleukin (Primary)
- Indications Malignant melanoma; Non-small cell lung cancer; Renal cell carcinoma; Solid tumours
- Focus Adverse reactions; First in man
- Acronyms EXCEL
- Sponsors Nektar Therapeutics
- 03 Feb 2020 According to a Nektar Therapeutics media release, data from this trial were presented in Nature Communications.
- 31 Oct 2018 Status changed from active, no longer recruiting to completed.
- 30 Oct 2017 Planned End Date changed from 1 Sep 2017 to 1 Jun 2018.